Charles River Laboratories International (CRL)

$230.09

-2.25

(-0.97%)▲

Market is closed - opens 7 PM, 18 Apr 2024

Insights on Charles River Laboratories International

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 1.05B → 1.01B (in $), with an average decrease of 2.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 87.38M → 187.08M (in $), with an average increase of 53.3% per quarter

  • Vs IQV

    In the last 1 year, Iqvia Holdings Inc. has given 13.1% return, outperforming this stock by 1.7%

  • Vs TMO

    In the last 3 years, Thermo Fisher Scientific, Inc. has given 6.3% return, outperforming this stock by 34.5%

Performance

  • $229.91
    $234.40
    $230.09
    downward going graph

    0.08%

    Downside

    Day's Volatility :1.92%

    Upside

    1.84%

    downward going graph
  • $161.65
    $275.00
    $230.09
    downward going graph

    29.74%

    Downside

    52 Weeks Volatility :41.22%

    Upside

    16.33%

    downward going graph

Returns

PeriodCharles River Laboratories InternationalSector (Health Care)S&P500
3 Months
14.16%
-0.5%
6.6%
6 Months
21.04%
5.9%
15.5%
1 Year
11.41%
3.1%
21.7%
3 Years
-28.42%
14.2%
20.7%

Highlights

Market Capitalization
12.2B
Book Value
$70.06
Earnings Per Share (EPS)
9.22
PE Ratio
25.59
PEG Ratio
1.87
Wall Street Target Price
270.8
Profit Margin
11.49%
Operating Margin TTM
14.52%
Return On Assets TTM
5.19%
Return On Equity TTM
14.38%
Revenue TTM
4.1B
Revenue Per Share TTM
80.61
Quarterly Revenue Growth YOY
-7.9%
Gross Profit TTM
1.5B
EBITDA
970.3M
Diluted Eps TTM
9.22
Quarterly Earnings Growth YOY
-0.01
EPS Estimate Current Year
11.02
EPS Estimate Next Year
12.43
EPS Estimate Current Quarter
2.4
EPS Estimate Next Quarter
2.51

Analyst Recommendation

Buy
    71%Buy
    28%Hold
    0
    0%Sell
Based on 21 Wall street analysts offering stock ratings for Charles River Laboratories International(by analysts ranked 0 to 5 stars)
Based on 21 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
16
Hold
6
5
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 17.69%

Current $230.09
Target $270.80

Company Financials

FY18Y/Y Change
Revenue
2.3B
↑ 21.99%
Net Income
226.4M
↑ 83.51%
Net Profit Margin
9.99%
↑ 3.35%
FY19Y/Y Change
Revenue
2.6B
↑ 15.67%
Net Income
252.0M
↑ 11.33%
Net Profit Margin
9.61%
↓ 0.38%
FY20Y/Y Change
Revenue
2.9B
↑ 11.55%
Net Income
364.3M
↑ 44.55%
Net Profit Margin
12.46%
↑ 2.85%
FY21Y/Y Change
Revenue
3.5B
↑ 21.08%
Net Income
391.0M
↑ 7.32%
Net Profit Margin
11.04%
↓ 1.42%
FY22Y/Y Change
Revenue
4.0B
↑ 12.31%
Net Income
486.2M
↑ 24.36%
Net Profit Margin
12.23%
↑ 1.19%
FY23Y/Y Change
Revenue
4.1B
↑ 3.86%
Net Income
474.6M
↓ 2.39%
Net Profit Margin
11.49%
↓ 0.74%
Q3 FY22Q/Q Change
Revenue
989.2M
↑ 1.65%
Net Income
96.5M
↓ 11.75%
Net Profit Margin
9.75%
↓ 1.48%
Q4 FY22Q/Q Change
Revenue
1.1B
↑ 11.19%
Net Income
187.4M
↑ 94.26%
Net Profit Margin
17.04%
↑ 7.29%
Q1 FY23Q/Q Change
Revenue
1.0B
↓ 6.41%
Net Income
103.1M
↓ 44.97%
Net Profit Margin
10.02%
↓ 7.02%
Q2 FY23Q/Q Change
Revenue
1.1B
↑ 2.97%
Net Income
97.0M
↓ 5.93%
Net Profit Margin
9.15%
↓ 0.87%
Q3 FY23Q/Q Change
Revenue
1.0B
↓ 3.14%
Net Income
87.4M
↓ 9.93%
Net Profit Margin
8.51%
↓ 0.64%
Q4 FY23Q/Q Change
Revenue
1.0B
↓ 1.28%
Net Income
187.1M
↑ 114.08%
Net Profit Margin
18.46%
↑ 9.95%
FY18Y/Y Change
Total Assets
3.9B
↑ 31.6%
Total Liabilities
2.5B
↑ 34.93%
FY19Y/Y Change
Total Assets
4.7B
↑ 21.7%
Total Liabilities
3.0B
↑ 20.21%
FY20Y/Y Change
Total Assets
5.5B
↑ 17.01%
Total Liabilities
3.3B
↑ 10.6%
FY21Y/Y Change
Total Assets
7.0B
↑ 27.93%
Total Liabilities
4.4B
↑ 32.42%
FY22Y/Y Change
Total Assets
7.6B
↑ 8.24%
Total Liabilities
4.6B
↑ 3.32%
FY23Y/Y Change
Total Assets
8.2B
↑ 7.79%
Total Liabilities
4.5B
↓ 0.94%
Q3 FY22Q/Q Change
Total Assets
7.4B
↓ 1.95%
Total Liabilities
4.7B
↓ 2.59%
Q4 FY22Q/Q Change
Total Assets
7.6B
↑ 2.98%
Total Liabilities
4.6B
↓ 2.79%
Q1 FY23Q/Q Change
Total Assets
7.7B
↑ 1.27%
Total Liabilities
4.5B
↓ 0.8%
Q2 FY23Q/Q Change
Total Assets
7.8B
↑ 0.95%
Total Liabilities
4.5B
↓ 1.55%
Q3 FY23Q/Q Change
Total Assets
7.6B
↓ 2.13%
Total Liabilities
4.3B
↓ 4.83%
Q4 FY23Q/Q Change
Total Assets
8.2B
↑ 7.73%
Total Liabilities
4.5B
↑ 6.57%
FY18Y/Y Change
Operating Cash Flow
441.1M
↑ 39.48%
Investing Cash Flow
-955.0M
↑ 1215.68%
Financing Cash Flow
558.1M
↓ 367.69%
FY19Y/Y Change
Operating Cash Flow
480.9M
↑ 9.02%
Investing Cash Flow
-681.5M
↓ 28.64%
Financing Cash Flow
231.9M
↓ 58.44%
FY20Y/Y Change
Operating Cash Flow
546.6M
↑ 13.65%
Investing Cash Flow
-601.5M
↓ 11.73%
Financing Cash Flow
47.2M
↓ 79.63%
FY21Y/Y Change
Operating Cash Flow
760.8M
↑ 39.19%
Investing Cash Flow
-1.4B
↑ 139.04%
Financing Cash Flow
672.6M
↑ 1323.55%
FY22Y/Y Change
Operating Cash Flow
619.6M
↓ 18.55%
Investing Cash Flow
-607.9M
↓ 57.72%
Financing Cash Flow
-42.4M
↓ 106.3%
Q3 FY22Q/Q Change
Operating Cash Flow
132.8M
↓ 11.17%
Investing Cash Flow
-652.3M
↑ 41.16%
Financing Cash Flow
-51.6M
↓ 119.01%
Q4 FY22Q/Q Change
Operating Cash Flow
234.8M
↑ 76.8%
Investing Cash Flow
44.4M
↓ 106.8%
Financing Cash Flow
-249.0M
↑ 382.53%
Q1 FY23Q/Q Change
Operating Cash Flow
109.4M
↓ 53.41%
Investing Cash Flow
-168.6M
↓ 479.92%
Financing Cash Flow
25.2M
↓ 110.14%
Q2 FY23Q/Q Change
Operating Cash Flow
148.1M
↑ 35.42%
Investing Cash Flow
-76.6M
↓ 54.57%
Financing Cash Flow
-71.5M
↓ 383.13%
Q3 FY23Q/Q Change
Operating Cash Flow
205.5M
↑ 38.7%
Investing Cash Flow
-324.8M
↑ 323.95%
Financing Cash Flow
-162.9M
↑ 127.9%

Technicals Summary

Sell

Neutral

Buy

Charles River Laboratories International is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Charles River Laboratories International
Charles River Laboratories International
-11.36%
21.04%
11.41%
-28.42%
74.04%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-7.6%
12.26%
1.67%
-7.38%
127.15%
Agilent Technologies Inc.
Agilent Technologies Inc.
-6.36%
21.71%
-2.42%
2.47%
81.36%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-4.4%
14.39%
-5.78%
13.72%
115.35%
Danaher Corp.
Danaher Corp.
-4.43%
13.4%
-6.03%
-0.68%
92.46%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-9.74%
15.15%
13.09%
5.98%
73.18%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Charles River Laboratories International
Charles River Laboratories International
25.59
25.59
1.87
11.02
0.14
0.05
NA
70.06
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
48.79
48.79
4.75
11.13
0.81
0.23
NA
17.88
Agilent Technologies Inc.
Agilent Technologies Inc.
33.55
33.55
2.7
5.5
0.21
0.08
0.01
21.12
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
36.11
36.11
2.81
21.56
0.13
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
42.34
42.34
3.13
7.62
0.08
0.04
0.0
72.36
Iqvia Holdings Inc.
Iqvia Holdings Inc.
31.74
31.74
1.33
11.11
0.23
0.05
NA
33.67
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Charles River Laboratories International
Charles River Laboratories International
Buy
$12.2B
74.04%
25.59
11.49%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$40.8B
127.15%
48.79
23.08%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$41.2B
81.36%
33.55
18.35%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$212.9B
115.35%
36.11
13.99%
Danaher Corp.
Danaher Corp.
Buy
$177.5B
92.46%
42.34
19.94%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$42.1B
73.18%
31.74
9.06%

Institutional Holdings

  • Vanguard Group Inc

    11.61%

  • BlackRock Inc

    10.02%

  • State Street Corporation

    4.00%

  • Kayne Anderson Rudnick Investment Management LLC

    3.40%

  • ClearBridge Advisors, LLC

    2.85%

  • T. Rowe Price Associates, Inc.

    2.80%

Company Information

charles river provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. #drugdiscovery #biotech #biotechnology #pharmaceuticals #cro

Organization
Charles River Laboratories International
Employees
20400
CEO
Mr. James C. Foster J.D.
Industry
Commercial Services

Discover More

FAQs